GSK3A and chronic myelogenous leukemia, BCR-ABL1 positive: Using a cell line model of TKI-resistant CML, we found that this regulation of NK cell activating ligands by GSK-3α was independent of an oncogenic BCR-ABL1 mutation conferring TKI resistance and occurred at the level of gene transcription as well as cell surface protein expression.